19 completed. 19 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 19 |
| Phase 3 | 2 | Completed 2 |
Follow amprenavir: new trials by email Literature Review of amprenavir trials Research Report on amprenavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of CNS-targeted HAART (CIT2) FDA Approved Antiretroviral Therapy (see list below) - HIV Infections | Phase 2 / Phase 3 | Completed | University of California, San Diego | 59 | 2007-03-01 | 2014-04-23 |
| Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients tipranavir, ritonavir, saquinavir - HIV Infections | Phase 2 | Completed | Boehringer Ingelheim | 328 | 2003-02-18 | 2023-12-01 |
| Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor Amprenavir/ritonavir, Saquinavir/ritonavir - HIV Infections | Phase 2 / Phase 3 | Completed | Abbott | 16 | 2001-04-01 | 2006-07-28 |
| Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART Amprenavir/ritonavir, Saquinavir/ritonavir, Efavirenz - HIV Infections | Phase 2 | Completed | Abbott | 24 | 2001-04-01 | 2008-04-01 |
| Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-infected Patients in Virological Failure. Amprenavir (drug), ABT-378/r (drug), Ritonavir (drug) - HIV Infections | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 100 | 2000-11-01 | 2026-06-15 |
| A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults Enfuvirtide, Ritonavir, Abacavir sulfate - HIV Infections | Phase 2 | Completed | Hoffmann-La Roche | 68 | 1999-05-01 | 2005-11-15 |
| Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV Ritonavir, Abacavir sulfate, Amprenavir - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 121 | 1999-05-01 | 2021-10-29 |
| A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir Indinavir sulfate, Abacavir sulfate, Amprenavir - HIV Infections | Phase 2 | Completed | Glaxo Wellcome | 100 | 1999-03-01 | 2005-06-24 |
| Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz Abacavir, Amprenavir, Efavirenz - HIV Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 25 | 1997-11-01 | 2008-03-04 |
| Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance Lopinavir/ritonavir, Ritonavir, Saquinavir - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 118 | 2011-03-01 | |
| A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir Indinavir sulfate, Amprenavir, Nevirapine - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 94 | 2021-11-04 | |
| A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients Amprenavir, Lamivudine, Zidovudine - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 94 | 2021-11-04 | |
| A Study of a Combination of Four Drugs in Patients With Recent HIV Infection Indinavir sulfate, Abacavir sulfate, Amprenavir - HIV Infections | Phase 2 | Completed | Glaxo Wellcome | 30 | 2005-06-24 | |
| Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment Abacavir sulfate, Amprenavir, Efavirenz - HIV Infections | Phase 2 | Completed | Gilead Sciences | 25 | 2005-06-24 | |
| A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment Ritonavir, Abacavir sulfate, Amprenavir - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 42 | 2021-11-01 | |
| A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 300 | 2012-05-21 | |
| A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients Indinavir sulfate, Abacavir sulfate, Amprenavir - HIV Infections | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 475 | 2021-10-29 | |
| The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients With HIV Who Developed a Resistance to Protease Inhibitors Abacavir sulfate, Amprenavir, Efavirenz - HIV Infections | Phase 2 | Completed | Glaxo Wellcome | 80 | 2005-06-24 | |
| A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Indinavir sulfate, Ritonavir, Abacavir sulfate - HIV Infections | Phase 2 | Completed | Glaxo Wellcome | 80 | 2005-06-24 |
HIV Infections (19) · AIDS Dementia Complex (1) · Acquired Immunodeficiency Syndrome (1) · Cognitive Dysfunction (1)
National Institute of Allergy and Infectious Diseases (NIAID) (8) · Glaxo Wellcome (4) · Abbott (2) · ANRS, Emerging Infectious Diseases (1) · Boehringer Ingelheim (1) · Gilead Sciences (1) · Hoffmann-La Roche (1) · University of California, San Diego (1)
United States (18) · France (4) · Puerto Rico (4) · Canada (3) · Italy (3) · United Kingdom (3) · Argentina (2) · Brazil (2) · Germany (2) · Poland (2) · Spain (2) · Australia (1) · Belgium (1) · Denmark (1) · Greece (1)
Eugene Sun, M.D. (2) · Gulick R (2) · Murphy R (2) · Scott Hammer (2) · Deborah McMahon, M.D. (1) · Elizabeth Connick, MD (1) · Genevieve Chene, MD, PhD (1) · Gilles Raguin, MD (1) · John Mellors (1) · Mary Albrecht (1) · Paul Volberding, MD (1) · Robert Murphy (1) · Ronald J Ellis, MD, PhD (1)
PMID 15060509, PMID 15456093, PMID 17726714, PMID 19696651, PMID 21337357, PMID 21637110, PMID 24352352
R01MH058076 (1)